About this Journal Submit a Manuscript Table of Contents
Journal of Oncology
Volume 2010 (2010), Article ID 412985, 17 pages
http://dx.doi.org/10.1155/2010/412985
Review Article

Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls

Department of Cell & Molecular Pharmacology, Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA

Received 25 December 2009; Accepted 12 April 2010

Academic Editor: Sundaram Ramakrishnan

Copyright © 2010 J. E. Bohonowych et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Folkman, “Tumor angiogenesis: therapeutic implications,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. View at Scopus
  2. M. Seandel, J. Butler, D. Lyden, and S. Raf, “A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization,” Cancer Cell, vol. 13, no. 3, pp. 181–183, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. Bergers and D. Hanahan, “Modes of resistance to anti-angiogenic therapy,” Nature Reviews Cancer, vol. 8, no. 8, pp. 592–603, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. Sanderson, M. Valenti, S. Gowan, L. Patterson, Z. Ahmad, P. Workman, and S. A. Eccles, “Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis,” Molecular Cancer Therapeutics, vol. 5, no. 3, pp. 522–532, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. L. Whitesell, S. D. Shifrin, G. Schwab, and L. M. Neckers, “Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition,” Cancer Research, vol. 52, no. 7, pp. 1721–1728, 1992. View at Scopus
  6. L. H. Pearl and C. Prodromou, “Structure and mechanism of the Hsp90 molecular chaperone machinery,” Annual Review of Biochemistry, vol. 75, pp. 271–294, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. S. Isaacs, W. Xu, and L. Neckers, “Heat shock protein 90 as a molecular target for cancer therapeutics,” Cancer Cell, vol. 3, no. 3, pp. 213–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. S. Isaacs, “Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 569–589, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. V. Powers and P. Workman, “Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors,” Endocrine-Related Cancer, vol. 13, supplement 1, pp. 125–135, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. L. Whitesell, R. Bagatell, and R. Falsey, “The stress response: implications for the clinical development of Hsp90 inhibitors,” Current Cancer Drug Targets, vol. 3, no. 5, pp. 349–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Neckers, “Hsp90 inhibitors as novel cancer chemotherapeutic agents,” Trends in Molecular Medicine, vol. 8, no. 4, pp. S55–S61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Roe, C. Prodromou, R. O'Brien, J. E. Ladbury, P. W. Piper, and L. H. Pearl, “Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin,” Journal of Medicinal Chemistry, vol. 42, no. 2, pp. 260–266, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. G. Supko, R. L. Hickman, M. R. Grever, and L. Malspeis, “Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent,” Cancer Chemotherapy and Pharmacology, vol. 36, no. 4, pp. 305–315, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. T. W. Schulte and L. M. Neckers, “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin,” Cancer Chemotherapy and Pharmacology, vol. 42, no. 4, pp. 273–279, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. Z.-Q. Tian, Y. Liu, and Y. Liu, “Synthesis and biological activities of novel 17-aminogeldanamycin derivatives,” Bioorganic and Medicinal Chemistry, vol. 12, no. 20, pp. 5317–5329, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. Z. Usmani, R. Bona, and Z. Li, “17 AAG for HSP90 inhibition in cancer—from bench to bedside,” Current Molecular Medicine, vol. 9, no. 5, pp. 654–664, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. H. M. Prince, M. J. Bishton, and R. W. Johnstone, “Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors,” Future Oncology, vol. 5, no. 5, pp. 601–612, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Y. S. Kim, S. V. Alarcon, S. Lee, M.-J. Lee, G. Giaccone, L. Neckers, and J. B. Trepel, “Update on Hsp90 inhibitors in clinical trial,” Current Topics in Medicinal Chemistry, vol. 9, no. 15, pp. 1479–1492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. G. L. Semenza, “Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics,” Oncogene, vol. 29, no. 5, pp. 625–634, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. G. L. Semenza, “Involvement of hypoxia-inducible factor 1 in human cancer,” Internal Medicine, vol. 41, no. 2, pp. 79–83, 2002. View at Scopus
  21. G. L. Semenza, “HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus,” Cell, vol. 107, no. 1, pp. 1–3, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Y. Koh and G. Powis, “HAF: the new player in oxygen-independent HIF-1α degradation,” Cell Cycle, vol. 8, no. 9, pp. 1359–1366, 2009. View at Scopus
  23. Y. S. Chun, M. S. Kim, and J. W. Park, “Oxygen-dependent and -independent regulation of HIF-1alpha,” Journal of Korean Medical Science, vol. 17, no. 5, pp. 581–588, 2002. View at Scopus
  24. K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, and W. G. Kaelin Jr., “Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein,” Cancer Cell, vol. 1, no. 3, pp. 237–246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. W. G. Kaelin Jr., “The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma,” Clinical Cancer Research, vol. 13, no. 2, pp. 680S–684S, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. E. B. Rankin and A. J. Giaccia, “The role of hypoxia-inducible factors in tumorigenesis,” Cell Death and Differentiation, vol. 15, no. 4, pp. 678–685, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. O. Iliopoulos, A. P. Levy, C. Jiang, W. G. Kaelin Jr., and M. A. Goldberg, “Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 10595–10599, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Liao and R. S. Johnson, “Hypoxia: a key regulator of angiogenesis in cancer,” Cancer and Metastasis Reviews, vol. 26, no. 2, pp. 281–290, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. W. Wang, W.-D. Jia, and W.-D. Jia, “Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma,” Digestive Diseases and Sciences, vol. 54, no. 10, pp. 2128–2136, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. D. Del Bufalo, L. Ciuffreda, D. Trisciuoglio, M. Desideri, F. Cognetti, G. Zupi, and M. Milella, “Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus,” Cancer Research, vol. 66, no. 11, pp. 5549–5554, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Puppo, F. Battaglia, C. Ottaviano, S. Delfino, D. Ribatti, L. Varesio, and M. C. Bosco, “Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1α and -2α,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 1974–1984, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. A. Rapisarda, B. Uranchimeg, O. Sordet, Y. Pommier, R. H. Shoemaker, and G. Melillo, “Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications,” Cancer Research, vol. 64, no. 4, pp. 1475–1482, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Y. Koh, T. Spivak-Kroizman, S. Venturini, S. Welsh, R. R. Williams, D. L. Kirkpatrick, and G. Powis, “Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α,” Molecular Cancer Therapeutics, vol. 7, no. 1, pp. 90–100, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. L. M. Greenberger, I. D. Horak, and I. D. Horak, “A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth,” Molecular Cancer Therapeutics, vol. 7, no. 11, pp. 3598–3608, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. E. Minet, D. Mottet, G. Michel, I. Roland, M. Raes, J. Remacle, and C. Michiels, “Hypoxia-induced activation of HIF-1: role of HIF-1α-Hsp90 interaction,” FEBS Letters, vol. 460, no. 2, pp. 251–256, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. D. M. Katschinski, L. Le, S. G. Schindler, T. Thomas, A. K. Voss, and R. H. Wenger, “Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1α stabilization,” Cellular Physiology and Biochemistry, vol. 14, no. 4-6, pp. 351–360, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. J. S. Isaacs, Y. J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttitta, and L. M. Neckers, “Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway,” Journal of Biological Chemistry, vol. 277, no. 33, pp. 29936–29944, 2002. View at Scopus
  38. J. Yang, L. Zhang, P. J. A. Erbel, K. H. Gardner, K. Ding, J. A. Garcia, and R. K. Bruick, “Functions of the Per/ARNT/Sim domains of the hypoxia-inducible factor,” Journal of Biological Chemistry, vol. 280, no. 43, pp. 36047–36054, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. M. Milkiewicz, J. L. Doyle, T. Fudalewski, E. Ispanovic, M. Aghasi, and T. L. Haas, “HIF-1α and HIF-2α play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle,” Journal of Physiology, vol. 583, no. 2, pp. 753–766, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. J. S. Isaacs, Y.-J. Jung, and L. Neckers, “Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1α by modulating an Hsp90-dependent regulatory pathway,” Journal of Biological Chemistry, vol. 279, no. 16, pp. 16128–16135, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. Y. V. Liu, J. H. Baek, H. Zhang, R. Diez, R. N. Cole, and G. L. Semenza, “RACK1 competes with HSP90 for binding to HIF-1α and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1α,” Molecular Cell, vol. 25, no. 2, pp. 207–217, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. S. Amir, R. Wang, J. W. Simons, and N. J. Mabjeesh, “SEPT9_v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation,” Journal of Biological Chemistry, vol. 284, no. 17, pp. 11142–11151, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. O. Alqawi, M. Moghaddas, and G. Singh, “Effects of geldanamycin on HIF-1α mediated angiogenesis and invasion in prostate cancer cells,” Prostate Cancer and Prostatic Diseases, vol. 9, no. 2, pp. 126–135, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. S. A. Lang, D. Klein, and D. Klein, “Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo,” Molecular Cancer Therapeutics, vol. 6, no. 3, pp. 1123–1132, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S. A. Lang, C. Moser, and C. Moser, “Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1α autocrine loop, and reduces orthotopic tumor growth,” Clinical Cancer Research, vol. 13, no. 21, pp. 6459–6468, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. Y. Mizukami, Y. Kohgo, and D. C. Chung, “Hypoxia inducible factor-1-independent pathways in tumor angiogenesis,” Clinical Cancer Research, vol. 13, no. 19, pp. 5670–5674, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. D. Martin, R. Galisteo, and Gutkind J. S., “CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex,” The Journal of Biological Chemistry, vol. 284, no. 10, pp. 6038–6042, 2009.
  48. D. J. Brat, A. C. Bellail, and E. G. Van Meir, “The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis,” Neuro-Oncology, vol. 7, no. 2, pp. 122–133, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. D. A. Chan, T. L.A. Kawahara, P. D. Sutphin, H. Y. Chang, J.-T. Chi, and A. J. Giaccia, “Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment,” Cancer Cell, vol. 15, no. 6, pp. 527–538, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. S. Huang, J. B. Robinson, A. DeGuzman, C. D. Bucana, and I. J. Fidler, “Blockade of nuclear factor-κb signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8,” Cancer Research, vol. 60, no. 19, pp. 5334–5339, 2000. View at Scopus
  51. J. Rius, M. Guma, and M. Guma, “NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α,” Nature, vol. 453, no. 7196, pp. 807–811, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. M. Broemer, D. Krappmann, and C. Scheidereit, “Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation,” Oncogene, vol. 23, no. 31, pp. 5378–5386, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. J. Crèvecoeur, M.-P. Merville, J. Piette, and G. Gloire, “Geldanamycin inhibits tyrosine phosphorylation-dependent NF-κB activation,” Biochemical Pharmacology, vol. 75, no. 11, pp. 2183–2191, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. G. Qing, P. Yan, Z. Qu, H. Liu, and G. Xiao, “Hsp90 regulates processing of NF-κB2 p100 involving protection of NF-κB-inducing kinase (NIK) from autophagy-mediated degradation,” Cell Research, vol. 17, no. 6, pp. 520–530, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. Lewis, A. Devin, A. Miller, Y. Lin, Y. Rodriguez, L. Neckers, and Z.-G. Liu, “Disruption of Hsp96 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-κB activation,” Journal of Biological Chemistry, vol. 275, no. 14, pp. 10519–10526, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Ammirante, A. Rosati, and A. Rosati, “The activity of hsp90α promoter is regulated by NF-κB transcription factors,” Oncogene, vol. 27, no. 8, pp. 1175–1178, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. A. Papapetropoulos, G. García-Cardeña, J. A. Madri, and W. C. Sessa, “Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells,” Journal of Clinical Investigation, vol. 100, no. 12, pp. 3131–3139, 1997. View at Scopus
  58. J. P. Cooke, “NO and angiogenesis,” Atherosclerosis Supplements, vol. 4, no. 4, pp. 53–60, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Van Buren II, E. R. Camp, A. D. Yang, M. J. Gray, F. Fan, R. Somcio, and L. M. Ellis, “The role of nitric oxide in mediating tumour blood flow,” Expert Opinion on Therapeutic Targets, vol. 10, no. 5, pp. 689–701, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. M. Duval, F. Le Bœuf, J. Huot, and J.-P. Gratton, “Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase,” Molecular Biology of the Cell, vol. 18, no. 11, pp. 4659–4668, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. J. Fontana, D. Fulton, and D. Fulton, “Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release,” Circulation Research, vol. 90, no. 8, pp. 866–873, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. J.-X. Chen and B. Meyrick, “Hypoxia increases Hsp90 binding to eNOS via PI3K-Akt in porcine coronary artery endothelium,” Laboratory Investigation, vol. 84, no. 2, pp. 182–190, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. F. Roviezzo, M. Bucci, and M. Bucci, “Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation,” FASEB Journal, vol. 20, no. 2, pp. 340–342, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. V. Anelli, C. R. Gault, A. B. Cheng, and L. M. Obeid, “Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells: Role of hypoxia-inducible factors 1 and 2,” Journal of Biological Chemistry, vol. 283, no. 6, pp. 3365–3375, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. M. D. Michaud, G. A. Robitaille, J.-P. Gratton, and D. E. Richard, “Sphingosine-1-phosphate: a novel nonhypoxic activator of hypoxia-inducible factor-1 in vascular cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 6, pp. 902–908, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. S. E. Schnitzer, A. Weigert, J. Zhou, and B. Brüne, “Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells,” Molecular Cancer Research, vol. 7, no. 3, pp. 393–401, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. S. Sato, N. Fujita, and T. Tsuruo, “Modulation of Akt kinase activity by binding to Hsp90,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10832–10837, 2000. View at Scopus
  68. A. Citri, D. Harari, and D. Harari, “Hsp90 recognizes a common surface on client kinases,” Journal of Biological Chemistry, vol. 281, no. 20, pp. 14361–14369, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. K. A. Pritchard Jr., A. W. Ackerman, and A. W. Ackerman, “Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 17621–17624, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. G. García-Cardeña, R. Fan, V. Shah, R. Sorrentino, G. Cirino, A. Papapetropoulos, and W. C. Sessa, “Dynamic activation of endothelial nitric oxide synthase by Hsp90,” Nature, vol. 392, no. 6678, pp. 821–824, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. J. Sun and J. K. Liao, “Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2238–2244, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. Y. Okawa, T. Hideshima, and T. Hideshima, “SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK,” Blood, vol. 113, no. 4, pp. 846–855, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. J. Y. Hsu and H. A. Wakelee, “Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy,” BioDrugs, vol. 23, no. 5, pp. 289–304, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. L. M. Ellis and D. J. Hicklin, “VEGF-targeted therapy: mechanisms of anti-tumour activity,” Nature Reviews Cancer, vol. 8, no. 8, pp. 579–591, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. M. C. Heinrich, C. L. Corless, and C. L. Corless, “Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4342–4349, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. J. A. Engelman and J. Settleman, “Acquired resistance to tyrosine kinase inhibitors during cancer therapy,” Current Opinion in Genetics and Development, vol. 18, no. 1, pp. 73–79, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. S. Yano, W. Wang, and W. Wang, “Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations,” Cancer Research, vol. 68, no. 22, pp. 9479–9487, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. L. Ellis and D. J. Hicklin, “Pathways mediating resistance to vascular endothelial growth factor-targeted therapy,” Clinical Cancer Research, vol. 14, no. 20, pp. 6371–6375, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. J. M. Stommel, A. C. Kimmelman, and A. C. Kimmelman, “Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies,” Science, vol. 318, no. 5848, pp. 287–290, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. L. Whitesell and S. L. Lindquist, “HSP90 and the chaperoning of cancer,” Nature Reviews Cancer, vol. 5, no. 10, pp. 761–772, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. D. George, “Platelet-derived growth factor receptors: a therapeutic target in solid tumors,” Seminars in Oncology, vol. 28, no. 5, pp. 27–33, 2001. View at Scopus
  82. D. Wang, H.-J. S. Huang, A. Kazlauskas, and W. K. Cavenee, “Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase,” Cancer Research, vol. 59, no. 7, pp. 1464–1472, 1999. View at Scopus
  83. L. J. Nissen, R. Cao, and R. Cao, “Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis,” Journal of Clinical Investigation, vol. 117, no. 10, pp. 2766–2777, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. R. Cao, A. Eriksson, H. Kubo, K. Alitalo, Y. Cao, and J. Thyberg, “Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis lymphangiogenesis, vascular fenestrations, and permeability,” Circulation Research, vol. 94, no. 5, pp. 664–670, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. P. A. Jänne, N. Gray, and J. Settleman, “Factors underlying sensitivity of cancers to small-molecule kinase inhibitors,” Nature Reviews Drug Discovery, vol. 8, no. 9, pp. 709–723, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. D. J. George, “Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma,” Clinical Cancer Research, vol. 13, no. 2, part 2, pp. 753–757, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P. M. Comoglio, “Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene,” Cancer Cell, vol. 3, no. 4, pp. 347–361, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Wojta, C. Kaun, and C. Kaun, “Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells,” Laboratory Investigation, vol. 79, no. 4, pp. 427–438, 1999. View at Scopus
  89. F. Koga, S. Tsutsumi, and L. M. Neckers, “Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells,” Cell Cycle, vol. 6, no. 11, pp. 1393–1402, 2007. View at Scopus
  90. A. M. Petit, J. Rak, M.-C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R. S. Kerbel, “Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors,” American Journal of Pathology, vol. 151, no. 6, pp. 1523–1530, 1997. View at Scopus
  91. Y. M. Lee, M. H. Bae, O. H. Lee, E. J. Moon, C. K. Moon, W. H. Kim, and K. W. Kim, “Synergistic induction of in vivo angiogenesis by the combination of insulin-like growth factor-II and epidermal growth factor,” Oncology Reports, vol. 12, no. 4, pp. 843–848, 2004. View at Scopus
  92. S. Wang, I. Pashtan, S. Tsutsumi, W. Xu, and L. Neckers, “Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors,” Cell Cycle, vol. 8, no. 13, pp. 2050–2056, 2009. View at Scopus
  93. R. Sordella, D. W. Bell, D. A. Haber, and J. Settleman, “Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways,” Science, vol. 305, no. 5687, pp. 1163–1167, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. J. G. Paez, P. A. Jänne, and P. A. Jänne, “EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis, “Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor,” Clinical Cancer Research, vol. 11, no. 1, pp. 397–405, 2005. View at Scopus
  96. I. R. Hutcheson, J. M. Knowlden, and J. M. Knowlden, “Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy,” Endocrine-Related Cancer, vol. 13, supplement 1, pp. 89–97, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. M. Guix, A. C. Faber, and A. C. Faber, “Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins,” Journal of Clinical Investigation, vol. 118, no. 7, pp. 2609–2619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. A. C. Faber, D. Li, and D. Li, “Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 46, pp. 19503–19508, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. C. Moser, P. Schachtschneider, and P. Schachtschneider, “Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis,” European Journal of Cancer, vol. 44, no. 11, pp. 1577–1586, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. C. P. Webb, C. D. Hose, and C. D. Hose, “The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network,” Cancer Research, vol. 60, no. 2, pp. 342–349, 2000. View at Scopus
  101. D. Matei, M. Satpathy, L. Cao, Y.-C. Lai, H. Nakshatri, and D. B. Donner, “The platelet-derived growth factor receptor α is destabilized by geldanamycins in cancer cells,” Journal of Biological Chemistry, vol. 282, no. 1, pp. 445–453, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. F. F. Zheng, S. D. Kuduk, G. Chiosis, P. N. Münster, L. Sepp-Lorenzino, S. J. Danishefsky, and N. Rosen, “Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases,” Cancer Research, vol. 60, no. 8, pp. 2090–2094, 2000. View at Scopus
  103. S. J. Lavictoire, D. A. E. Parolin, A. C. Klimowicz, J. F. Kelly, and I. A. J. Lorimer, “Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII,” Journal of Biological Chemistry, vol. 278, no. 7, pp. 5292–5299, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. T. Shimamura, A. M. Lowell, J. A. Engelman, and G. I. Shapiro, “Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins,” Cancer Research, vol. 65, no. 14, pp. 6401–6408, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. S. Modi, A. T. Stopeck, and A. T. Stopeck, “Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: a phase I dose-escalation study,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5410–5417, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. H.-J. Ochel, T. W. Schulte, P. Nguyen, J. Trepel, and L. Neckers, “The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase,” Molecular Genetics and Metabolism, vol. 66, no. 1, pp. 24–30, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. T. W. Schulte, M. V. Blagosklonny, and M. V. Blagosklonny, “Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf- 1-MEK-mitogen-activated protein kinase signalling pathway,” Molecular and Cellular Biology, vol. 16, no. 10, pp. 5839–5845, 1996. View at Scopus
  108. D. B. Solit, A. D. Basso, A. B. Olshen, H. I. Scher, and N. Rosen, “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol,” Cancer Research, vol. 63, no. 9, pp. 2139–2144, 2003. View at Scopus
  109. L. K. Francis, Y. Alsayed, and Y. Alsayed, “Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma,” Clinical Cancer Research, vol. 12, no. 22, pp. 6826–6835, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. D. R. Premkumar, B. Arnold, and I. F. Pollack, “Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth,” Molecular Carcinogenesis, vol. 45, no. 5, pp. 288–301, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. M. A. Park, G. Zhang, and G. Zhang, “Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95,” Molecular Cancer Therapeutics, vol. 7, no. 9, pp. 2633–2648, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. J. S. Abramson, W. Chen, and W. Chen, “The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas,” British Journal of Haematology, vol. 144, no. 3, pp. 358–366, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. E. B. Pasquale, “Eph-ephrin bidirectional signaling in physiology and disease,” Cell, vol. 133, no. 1, pp. 38–52, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. D. M. Brantley-Sieders, J. Caughron, D. Hicks, A. Pozzi, J. C. Ruiz, and J. Chen, “EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation,” Journal of Cell Science, vol. 117, no. 10, pp. 2037–2049, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. D. M. Brantley-Sieders, G. Zhuang, and G. Zhuang, “The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling,” Journal of Clinical Investigation, vol. 118, no. 1, pp. 64–78, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. D. M. Brantley-Sieders and J. Chen, “Eph receptor tyrosine kinases in angiogenesis: from development to disease,” Angiogenesis, vol. 7, no. 1, pp. 17–28, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. M. Héroult, F. Schaffner, and H. G. Augustin, “Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression,” Experimental Cell Research, vol. 312, no. 5, pp. 642–650, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. N. K. Noren and E. B. Pasquale, “Paradoxes of the EphB4 receptor in cancer,” Cancer Research, vol. 67, no. 9, pp. 3994–3997, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  119. J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski, “EphA2 as a novel molecular marker and target in glioblastoma multiforme,” Molecular Cancer Research, vol. 3, no. 10, pp. 541–551, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. H. Miao, D.-Q. Li, and D.-Q. Li, “EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt,” Cancer Cell, vol. 16, no. 1, pp. 9–20, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. C. N. Landen Jr., A. Chavez-Reyes, C. Bucana, R. Schmandt, M. T. Deavers, G. Lopez-Berestein, and A. K. Sood, “Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery,” Cancer Research, vol. 65, no. 15, pp. 6910–6918, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. C. N. Landen, C. Lu, and C. Lu, “Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer,” Journal of the National Cancer Institute, vol. 98, no. 21, pp. 1558–1570, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. B. Annamalai, X. Liu, U. Gopal, and J. S. Isaacs, “Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis,” Molecular Cancer Research, vol. 7, no. 7, pp. 1021–1032, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. M. Macrae, R. M. Neve, and R. M. Neve, “A conditional feedback loop regulates Ras activity through EphA2,” Cancer Cell, vol. 8, no. 2, pp. 111–118, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. A. B. Larsen, M. W. Pedersen, M.-T. Stockhausen, M. V. Grandal, B. Van Deurs, and H. S. Poulsen, “Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility,” Molecular Cancer Research, vol. 5, no. 3, pp. 283–293, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. D. M. Brantley-Sieders, W. B. Fang, Y. Hwang, D. Hicks, and J. Chen, “Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice,” Cancer Research, vol. 66, no. 21, pp. 10315–10324, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. Y. R. Chin and A. Toker, “Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer,” Cellular Signalling, vol. 21, no. 4, pp. 470–476, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. S. Chandarlapaty, A. Sawai, and A. Sawai, “SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase—dependent cancers,” Clinical Cancer Research, vol. 14, no. 1, pp. 240–248, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. A. Franovic, C. E. Holterman, J. Payette, and S. Lee, “Human cancers converge at the HIF-2α oncogenic axis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 50, pp. 21306–21311, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. K. Burkitt, S. Y. Chun, D. T. Dang, and L. H. Dang, “Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment,” Molecular Cancer Therapeutics, vol. 8, no. 5, pp. 1148–1156, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. E. I. Heath, D. W. Hillman, and D. W. Hillman, “A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7940–7946, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. E. A. Ronnen, G. V. Kondagunta, and G. V. Kondagunta, “A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma,” Investigational New Drugs, vol. 24, no. 6, pp. 543–546, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. L. R. Kelland, S. Y. Sharp, P. M. Rogers, T. G. Myers, and P. Workman, “DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17- demethoxygeldanamycin, an inhibitor of heat shock protein 90,” Journal of the National Cancer Institute, vol. 91, no. 22, pp. 1940–1949, 1999. View at Scopus
  134. N. Gaspar, S. Y. Sharp, and S. Y. Sharp, “Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells,” Cancer Research, vol. 69, no. 5, pp. 1966–1975, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross, “Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition,” Cancer Research, vol. 65, no. 21, pp. 10006–10015, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. W. Guo, P. Reigan, D. Siegel, and D. Ross, “Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action,” Drug Metabolism and Disposition, vol. 36, no. 10, pp. 2050–2057, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  137. G. Chiosis, B. Lucas, A. Shtil, H. Huezo, and N. Rosen, “Development of a purine-scaffold novel class of hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase,” Bioorganic and Medicinal Chemistry, vol. 10, no. 11, pp. 3555–3564, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. D. B. Solit and G. Chiosis, “Development and application of Hsp90 inhibitors,” Drug Discovery Today, vol. 13, no. 1-2, pp. 38–43, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  139. S. A. Eccles, A. Massey, and A. Massey, “NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis,” Cancer Research, vol. 68, no. 8, pp. 2850–2860, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. R. Bagatell, G. D. Paine-Murrieta, C. W. Taylor, E. J. Pulcini, S. Akinaga, I. J. Benjamin, and L. Whitesell, “Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90-binding agents,” Clinical Cancer Research, vol. 6, no. 8, pp. 3312–3318, 2000. View at Scopus
  141. A. K. McCollum, C. J. TenEyck, B. M. Sauer, D. O. Toft, and C. Erlichman, “Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism,” Cancer Research, vol. 66, no. 22, pp. 10967–10975, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  142. A. K. McCollum, C. J. TenEyck, and C. J. TenEyck, “P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response,” Cancer Research, vol. 68, no. 18, pp. 7419–7427, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  143. M. V. Powers, P. A. Clarke, and P. Workman, “Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis,” Cancer Cell, vol. 14, no. 3, pp. 250–262, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  144. C. Dai, L. Whitesell, A. B. Rogers, and S. Lindquist, “Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis,” Cell, vol. 130, no. 6, pp. 1005–1018, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  145. A. K. McCollum, K. B. Lukasiewicz, C. J. TenEyck, W. L. Lingle, D. O. Toft, and C. Erlichman, “Cisplatin abrogates the geldanamycin-induced heat shock response,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3256–3264, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  146. J. H. Baek, Y. V. Liu, K. R. McDonald, J. B. Wesley, H. Zhang, and G. L. Semenza, “Spermidine/spermine N1-acetyltransferase-1 binds to hypoxia-inducible factor-1α (HIF-1α) and RACK1 and promotes ubiquitination and degradation of HIF-1α,” Journal of Biological Chemistry, vol. 282, no. 46, pp. 33358–33366, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  147. Y. V. Liu, M. E. Hubbi, and M. E. Hubbi, “Calcineurin promotes hypoxia-inducible factor 1α expression by dephosphorylating RACK1 and blocking RACK1 dimerization,” Journal of Biological Chemistry, vol. 282, no. 51, pp. 37064–37073, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  148. E. S. Ehrlich, T. Wang, and T. Wang, “Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20330–20335, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  149. M. J. Fay, K. A. Longo, and K. A. Longo, “Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues,” Molecular Cancer, vol. 2, p. 40, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  150. C. Morrissey and R. L. Vessella, “The role of tumor microenvironment in prostate cancer bone metastasis,” Journal of Cellular Biochemistry, vol. 101, no. 4, pp. 873–886, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  151. A. Orimo, P. B. Gupta, and P. B. Gupta, “Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion,” Cell, vol. 121, no. 3, pp. 335–348, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  152. P. A. Kenny, G. Y. Lee, and M. J. Bissell, “Targeting the tumor microenvironment,” Frontiers in Bioscience, vol. 12, pp. 3468–3474, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. A. F. Olumi, P. Dazin, and T. D. Tlsty, “A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death,” Cancer Research, vol. 58, no. 20, pp. 4525–4530, 1998. View at Scopus
  154. J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley, “Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling,” Clinical Cancer Research, vol. 8, no. 9, pp. 2912–2923, 2002. View at Scopus
  155. J. A. Tuxhorn, S. J. McAlhany, T. D. Dang, G. E. Ayala, and D. R. Rowley, “Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model,” Cancer Research, vol. 62, no. 11, pp. 3298–3307, 2002. View at Scopus
  156. S. W. Hayward, Y. Wang, and Y. Wang, “Malignant transformation in a nontumorigenic human prostatic epithelial cell line,” Cancer Research, vol. 61, no. 22, pp. 8135–8142, 2001. View at Scopus
  157. M. Hu, J. Yao, and J. Yao, “Regulation of in situ to invasive breast carcinoma transition,” Cancer Cell, vol. 13, no. 5, pp. 394–406, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  158. M. Erkan, C. Reiser-Erkan, and C. Reiser-Erkan, “Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma,” Neoplasia, vol. 11, no. 5, pp. 497–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. Y.-F. Shi, C.-C. Fong, Q. Zhang, P.-Y. Cheung, C.-H. Tzang, R. S. S. Wu, and M. Yang, “Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-β signaling pathway,” FEBS Letters, vol. 581, no. 2, pp. 203–210, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  160. A. Masamune, K. Kikuta, T. Watanabe, K. Satoh, M. Hirota, and T. Shimosegawa, “Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer,” American Journal of Physiology, vol. 295, no. 4, pp. G709–G717, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  161. J. A. Joyce, “Therapeutic targeting of the tumor microenvironment,” Cancer Cell, vol. 7, no. 6, pp. 513–520, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  162. Y. Liu, X. M. Wen, and X. M. Wen, “Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258,” Laboratory Investigation, vol. 89, no. 10, pp. 1152–1160, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  163. Y. Liu, E. L. H. Lui, and E. L. H. Lui, “PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling,” Laboratory Investigation, vol. 89, no. 2, pp. 209–221, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  164. S. Tugues, G. Fernandez-Varo, and G. Fernandez-Varo, “Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats,” Hepatology, vol. 46, no. 6, pp. 1919–1926, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  165. V. Gioni, T. Karampinas, G. Voutsinas, A. E. Roussidis, S. Papadopoulos, N. K. Karamanos, and D. Kletsas, “Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts,” Molecular Cancer Research, vol. 6, no. 5, pp. 706–714, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  166. X. Guo, H. Oshima, T. Kitmura, M. M. Taketo, and M. Oshima, “Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer,” Journal of Biological Chemistry, vol. 283, no. 28, pp. 19864–19871, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  167. S. J. Myung, J.-H. Yoon, B. H. Kim, J.-H. Lee, E. U. Jung, and H.-S. Lee, “Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 1, pp. 276–282, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  168. G. Bergers and S. Song, “The role of pericytes in blood-vessel formation and maintenance,” Neuro-Oncology, vol. 7, no. 4, pp. 452–464, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  169. N. Reinmuth, W. Liu, and W. Liu, “Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival,” FASEB Journal, vol. 15, no. 7, pp. 1239–1241, 2001. View at Scopus
  170. S. Song, A. J. Ewald, W. Stallcup, Z. Werb, and G. Bergers, “PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival,” Nature Cell Biology, vol. 7, no. 9, pp. 870–879, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  171. K. Pietras, J. Pahler, G. Bergers, and D. Hanahan, “Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting,” PLoS Medicine, vol. 5, no. 1, article e19, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  172. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M. F. Boehm, L. C. Fritz, and F. J. Burrows, “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors,” Nature, vol. 425, no. 6956, pp. 407–410, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  173. G. Chiosis, H. Huezo, N. Rosen, E. Mimnaugh, L. Whitesell, and L. Neckers, “17AAG: low target binding affinity and potent cell activity–finding an explanation,” Molecular Cancer Therapeutics, vol. 2, no. 2, pp. 123–129, 2003. View at Scopus
  174. D. C. Radisky, “Fibroblasts act as co-conspirators for chemotherapy resistance,” Cancer Biology and Therapy, vol. 7, no. 9, pp. 1348–1349, 2008. View at Scopus
  175. Y. Crawford, I. Kasman, and I. Kasman, “PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment,” Cancer Cell, vol. 15, no. 1, pp. 21–34, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  176. J. J. Virrey, E. B. Golden, and E. B. Golden, “Glioma-associated endothelial cells are chemoresistant to temozolomide,” Journal of Neuro-Oncology, vol. 95, no. 1, pp. 13–22, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  177. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan, “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,” Journal of Clinical Investigation, vol. 111, no. 9, pp. 1287–1295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  178. K. E. Hovinga, L. J. Stalpers, C. van Bree, et al., “Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines–a clue to radioresistance?” Journal of Neuro-Oncology, vol. 74, no. 2, pp. 99–103, 2005.
  179. L. W. Chung, W. C. Huang, and W. C. Huang, “Stromal-epithelial interaction in prostate cancer progression,” Clinical Genitourinary Cancer, vol. 5, no. 2, pp. 162–170, 2006. View at Scopus
  180. N. Kamochi, M. Nakashima, S. Aoki, K. Uchihashi, H. Sugihara, S. Toda, and S. Kudo, “Irradiated fibroblast-induced bystander effects on invasive growth of squamous cell carcinoma under cancer-stromal cell interaction,” Cancer Science, vol. 99, no. 12, pp. 2417–2427, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  181. B. J. Moeller, Y. Cao, C. Y. Li, and M. W. Dewhirst, “Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules,” Cancer Cell, vol. 5, no. 5, pp. 429–441, 2004. View at Publisher · View at Google Scholar · View at Scopus
  182. B. J. Moeller, M. R. Dreher, Z. N. Rabbani, T. Schroeder, Y. Cao, C. Y. Li, and M. W. Dewhirst, “Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity,” Cancer Cell, vol. 8, no. 2, pp. 99–110, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  183. J. Brieger, J. Kattwinkel, M. Berres, J. Gosepath, and W. J. Mann, “Impact of vascular endothelial growth factor release on radiation resistance,” Oncology Reports, vol. 18, no. 6, pp. 1597–1601, 2007. View at Scopus
  184. R. F. Hwang, T. Moore, and T. Moore, “Cancer-associated stromal fibroblasts promote pancreatic tumor progression,” Cancer Research, vol. 68, no. 3, pp. 918–926, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  185. K. K. C. Tsai, J. Stuart, Y.-Y.E. Chuang, J. B. Little, and Z.-M. Yuan, “Low-dose radiation-induced senescent stromal fibroblasts render nearby breast cancer cells radioresistant,” Radiation Research, vol. 172, no. 3, pp. 306–313, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  186. M. Li, G. Ping, and G. Ping, “Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells,” BMC Cancer, vol. 6, article 79, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  187. K. S. Bisht, C. M. Bradbury, and C. M. Bradbury, “Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity,” Cancer Research, vol. 63, no. 24, pp. 8984–8995, 2003. View at Scopus
  188. J. S. Russell, W. Burgan, K. A. Oswald, K. Camphausen, and P. J. Tofilon, “Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization,” Clinical Cancer Research, vol. 9, no. 10, pp. 3749–3755, 2003. View at Scopus
  189. X. Yin, H. Zhang, K. Lundgren, L. Wilson, F. Burrows, and C. G. Shores, “BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy,” International Journal of Cancer, vol. 126, no. 5, pp. 1216–1225, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  190. D. L. Schwartz, G. Powis, and G. Powis, “The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects,” Molecular Cancer Therapeutics, vol. 8, no. 4, pp. 947–958, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  191. A. E. Kabakov, Y. M. Makarova, and Y. V. Malyutina, “Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 3, pp. 858–865, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  192. F. Winkler, S. V. Kozin, and S. V. Kozin, “Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases,” Cancer Cell, vol. 6, no. 6, pp. 553–563, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  193. P. J. Mishra, P. J. Mishra, and P. J. Mishra, “Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells,” Cancer Research, vol. 68, no. 11, pp. 4331–4339, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  194. R. S. Kerbel, R. Benezra, and R. Benezra, “Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, p. E54, 2008, author reply E55. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  195. D. K. Jin, K. Shido, and K. Shido, “Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes,” Nature Medicine, vol. 12, no. 5, pp. 557–567, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  196. S. Rey, K. Lee, and K. Lee, “Synergistic effect of HIF-1α gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20399–20404, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  197. G. Tabatabai, B. Frank, R. Möhle, M. Weller, and W. Wick, “Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-β-dependent HIF-1α-mediated induction of CXCL12,” Brain, vol. 129, no. 9, pp. 2426–2435, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  198. M. Pàez-Ribes, E. Allen, and E. Allen, “Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis,” Cancer Cell, vol. 15, no. 3, pp. 220–231, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  199. F. Shojaei, X. Wu, and X. Wu, “Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells,” Nature Biotechnology, vol. 25, no. 8, pp. 911–920, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  200. R. Du, K. V. Lu, and K. V. Lu, “HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion,” Cancer Cell, vol. 13, no. 3, pp. 206–220, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  201. F. Shojaei, X. Wu, and X. Wu, “Bv8 regulates myeloid-cell-dependent tumour angiogenesis,” Nature, vol. 450, no. 7171, pp. 825–831, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  202. B. Weigelt, A. T. Lo, C. C. Park, J. W. Gray, and M. J. Bissell, “HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment,” Breast Cancer Research and Treatment, vol. 122, no. 1, pp. 35–43, 2010.
  203. A. Mammoto, K. M. Connor, and K. M. Connor, “A mechanosensitive transcriptional mechanism that controls angiogenesis,” Nature, vol. 457, no. 7233, pp. 1103–1108, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  204. O. Ayrault, M. D. Godeny, C. Dillon, F. Zindy, P. Fitzgerald, M. F. Roussel, and H. M. Beere, “Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 40, pp. 17037–17042, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  205. E. Caldas-Lopes, L. Cerchietti, and L. Cerchietti, “Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 20, pp. 8368–8373, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  206. E. D. Pleasance, R. K. Cheetham, and R. K. Cheetham, “A comprehensive catalogue of somatic mutations from a human cancer genome,” Nature, vol. 463, no. 7278, pp. 191–196, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  207. E. D. Pleasance, P. J. Stephens, and P. J. Stephens, “A small-cell lung cancer genome with complex signatures of tobacco exposure,” Nature, vol. 463, no. 7278, pp. 184–190, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  208. W. Arap, M. G. Kolonin, and M. G. Kolonin, “Steps toward mapping the human vasculature by phage display,” Nature Medicine, vol. 8, no. 2, pp. 121–127, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  209. J. A. Joyce, P. Laakkonen, M. Bernasconi, G. Bergers, E. Ruoslahti, and D. Hanahan, “Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis,” Cancer Cell, vol. 4, no. 5, pp. 393–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  210. J. A. Hoffman, E. Giraudo, and E. Giraudo, “Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma,” Cancer Cell, vol. 4, no. 5, pp. 383–391, 2003. View at Publisher · View at Google Scholar · View at Scopus
  211. P. Olson, J. Lu, and J. Lu, “MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer,” Genes and Development, vol. 23, no. 18, pp. 2152–2165, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  212. D. Song, R. Chaerkady, and R. Chaerkady, “Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3275–3284, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  213. E. A. Eisenhauer, P. Therasse, and P. Therasse, “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  214. D. B. Solit, I. Osman, and I. Osman, “Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma,” Clinical Cancer Research, vol. 14, no. 24, pp. 8302–8307, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  215. W. Cai, A. Ebrahimnejad, K. Chen, Q. Cao, Z.-B. Li, D. A. Tice, and X. Chen, “Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 12, pp. 2024–2036, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  216. P. M. Smith-Jones, D. B. Solit, T. Akhurst, F. Afroze, N. Rosen, and S. M. Larson, “Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors,” Nature Biotechnology, vol. 22, no. 6, pp. 701–706, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  217. T. T. Batchelor, A. G. Sorensen, and A. G. Sorensen, “AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients,” Cancer Cell, vol. 11, no. 1, pp. 83–95, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  218. L. Xu, D. G. Duda, E. di Tomaso, et al., “Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer,” Cancer Research, vol. 69, no. 20, pp. 7905–7910, 2009.